Collaborative development, Mutation-agnostic Duchenne muscular dystrophy (DMD) treatment by anti-miR 33 ASO program

Asset: Mutation-agnostic Duchenne muscular dystrophy (DMD) program

Luxna Biotech’s lead program targets Duchenne muscular dystrophy using a mutation-independent approach, addressing a critical limitation of current exon-skipping therapies that are applicable only to specific genetic subtypes.

Modality: Antisense oligonucleotide (ASO)

The program leverages Luxna’s proprietary ASO chemistry to achieve durable in vivo efficacy with reduced toxicity, enabling systemic administration without complex delivery systems.

Mechanism of Action:

The lead asset is an anti-miR-33 ASO designed to modulate disease-relevant molecular pathways involved in muscle degeneration and regeneration. By targeting miRNA regulation rather than the dystrophin gene itself, the therapy is applicable regardless of the underlying DMD mutation, offering the potential for broad patient coverage.

Indication: Duchenne muscular dystrophy

Robust in vivo proof-of-concept has been demonstrated in severe DMD mouse models, showing improvements in motor function and muscle pathology.